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ABSTRACT
Tra2b regulates a number of splicing switches
including activation of the human testis-specific
exon HIPK3-T in the Homeodomain Interacting
Protein Kinase 3 gene. By testing HIPK3-T exons
of different intrinsic strengths, we found Tra2b
most efficiently activated splicing inclusion of intrin-
sically weak exons, although these were spliced at a
lower overall level. Both the RRM and N-terminal
RS-rich region of Tra2b were required for splicing
activation. Bioinformatic searches for splicing
enhancers and repressors mapped four physically
distinct exonic splicing enhancers (ESEs) within
HIPK3-T, each containing the known Tra2b
AGAA-rich binding site. Surprisingly disruption of
each single ESE prevented Tra2b-mediated activa-
tion, although single mutated exons could still bind
Tra2b protein by gel shifts and functional splicing
analyses. Titration experiments indicate an additive
model of HIPK3-T splicing activation, requiring
availability of an array of four distinct ESEs to
enable splicing activation. To enable this efficient
Tra2b-mediated splicing switch to operate, a
closely adjacent downstream and potentially com-
petitive stronger 50-splice site is actively repressed.
Our data indicate that a novel arrangement of
multiple mono-specific AGAA-rich ESEs coupled to
a weak 50-splice site functions as a responsive
gauge. This gauge monitors changes in the
specific nuclear concentration of the RNA binding
protein Tra2b, and co-ordinately regulates HIPK3-T
exon splicing inclusion.
INTRODUCTION
In excess of 90% of human genes encode more than one
mRNA isoform, with alternative splicing making an im-
portant contribution (1–3). Alternative splicing patterns of
pre-mRNAs can be modulated in response to the concen-
tration of speciﬁc nuclear RNA binding proteins within
particular cells and tissues (4,5). The biological effect of
splicing regulators is mediated through interpretation of
an intrinsic splicing code embedded within pre-mRNA se-
quences. Individual splicing factors can both activate and
repress exon inclusion, depending on where they bind in
target pre-mRNAs (6,7). Although alternative splicing is
found in every tissue, particularly high levels have been
observed in the human brain and testes (8–11). The target
sites for RNA binding proteins which make up the splicing
code are being deciphered by experiments and bioinfor-
matics (12), and must explain why some exons are spliced
with wide anatomic distributions, while others have much
more restricted tissue-speciﬁc patterns of splicing
inclusion.
The SR family are an important class of splicing regu-
lator proteins which contain domains enriched in arginine
and serine residues (RS domains). Classical SR protein
splicing regulators typically have one or two RNA recog-
nition motifs (RRMs) required for binding to their target
pre-mRNAs, and a C-terminal RS domain (13,14). The
SR-like splicing regulator protein Tra2 is conserved
between fruit ﬂies and humans. Tra2 has an unusual
modular structure compared with ‘classical’ SR proteins,
with a central RRM ﬂanked on the N-terminal side by a
protein sequence enriched in arginine–serine (RS) dipep-
tides (19 RS dipeptides in humans), and on the C-terminal
side by a hinge region and a smaller RS-rich region (seven
RS dipeptides in humans). Tra2b protein binds most
strongly to an AGAA target RNA sequence (15,16).
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concentrations of Tra2 (17–19). Amongst its known
molecular targets, Drosophila Tra2 protein regulates a
splicing switch in sex determination (20,21) and human
Tra2b protein regulates a splicing switch in the tissue-
speciﬁc exon HIPK3-T (19). The HIPK3-T exon is
within the Homeodomain Interacting Protein Kinase 3
gene, which is implicated in apoptotic control. HIPK3-T
is selected only in a single tissue, the testis, which has
elevated Tra2b concentrations.
The mechanisms through which ubiquitously expressed
factors like Tra2b can generate splicing switches in par-
ticular tissues are not well understood. To address this
question, here we functionally dissected the sequences
needed for splicing activation of HIPK3-T. We ﬁnd that
an array of exonic splicing enhancers responsive to Tra2b,
coupled to a weak 50-splice site act together as a gauge to
enable splicing activation in response to increased nuclear
concentrations of Tra2b. We show that this switch is deli-
cately balanced by the interplay between Tra2b binding
and 50-splice site strength, allowing activation of alterna-
tive splicing within a narrow window, outside which the
exon is either invisible to the spliceosome or activated
constitutively.
MATERIALS AND METHODS
Computational analysis of putative ESE/ESS content
of HIPK3-T and ﬂanking introns
We used CisPlotter (unpublished), to compare and design
HIPK3-T derivative sequences. Brieﬂy, this program
computes and plots the ESE or ESS score as shown in
Figure 1A. We used the list of putative ESE and ESS
octamers, chose the threshold z-score levels and dealt
with overlapping motifs as described previously (22).
This script accepts alternative nucleotides at speciﬁed pos-
itions and plots the resulting change in ESE or ESS scores
in a different colour to facilitate mutagenesis design
(Figure 3A).
Constructs
Minigene splicing constructs were based on the wild-type
HIPK3-T exon, and 269 and 267-nt upstream and down-
stream ﬂanking intron sequence respectively, cloned into
pXJ-41 as described previously (19). Site Directed
Mutagenesis of HIPK3-T was carried out as previously
described (22), mutants were veriﬁed by sequencing, and
then subcloned back into the parent plasmid.
Deletion versions of human Tra2b protein were
cloned in frame into pGFP3 using standard cloning tech-
niques (19,23). Tra2bDRS1 is missing amino acids 13–97,
Tra2bDRRM is missing amino acids 119–168,
Tra2bDRNP1 is missing amino acids 150–168 (Figure 2).
For expression of full length Tra2b, its coding sequence
was inserted in a pTT3 plasmid (24), in which a Flag tag
was previously inserted in the Hind III site.
Minigene splicing analysis of HIPK3-T exon variants
Tissue culture, transfections of HEK293 cells, RNA puri-
ﬁcation and RT–PCR was carried out using primers and
conditions as previously described (19) and the RT–PCR
products were analysed by capillary gel electrophoresis.
The HIPK3-T reporter construct (100ng) was transfected
with or without 300ng of Tra2b expressing plasmid using
GeneJammer (Agilent) under standard conditions for
24h. To enable analysis of splicing patterns as well as
monitoring the expression of transfected splicing factors,
transfected cell cultures were split into two portions and
analysed by western blotting as previously described (23).
Splicing was analysed as both a percentage splicing in-
clusion and a logarithmic splicing inclusion. We deﬁne
log-score as the natural logarithm of the ratio of HIPK3
exon T inclusion to exclusion (logit transformation).
Therefore there is a one-to-one mapping between percent-
age inclusion values and log-score values. A log-score
of zero denotes 50% inclusion of the HIPK3 exon T. A
positive log-score denotes >50% inclusion and a negative
log-score denotes <50% exon inclusion. Note that the log-
score values are unbounded and can theoretically range
between+/– inﬁnity. In reality they will be limited by the
resolution capability of band detection, which here we
have taken to be 0.1% which corresponds to a limit on
the log-score value of  6.9.
To compare intrinsic splicing capability of two con-
structs, the difference of the two log-scores is taken.
This procedure has several beneﬁts over comparing fold
change of the percentage inclusion values. Since the per-
centage inclusion values are bounded at 0 and 100%, fold
change comparisons close to these boundaries are mislead-
ing. In contrast the log-score method has been designed to
treat these two ends symmetrically. For example, percent-
age splicing inclusion changes from 2 to 5%; 95 to 98% or
40 to 64% each have a log-score difference of  1, whereas
the percentage inclusion fold change values would be 2.5,
1.03 and 1.6 respectively.
RNA afﬁnity assay and EMSA
HIPK3-T exon variants or the downstream intron were
cloned from the minigene splicing analysis constructs in
pXJ41 vector into pBluescript, and then in vitro
transcribed RNAs prepared as described (23). RNA
afﬁnity assays used in vitro transcribed RNAs attached
to sepharose beads to pull down proteins from nuclear
extracts as previously described (19). We tested for
binding of candidate RNA binding proteins based on
previous results (19) and on the availability of antisera.
The sequences of RNAs used for electromobility shift
assays (EMSAs) included the HIPK3-T exon and 11nt
of the upstream intron for wild-type or HIPK3-T exon
derivatives B4, B5 and B6. Sequences are detailed in
Table 1. Full length Tra2b was expressed at high level
by transient transfection of suspension 293-EBNA cells
(24) using FreeStyle 293-F cells, and FreeStyle expression
medium according to the recommendations of Invitrogen.
After 60h transfection, 293-F cells were pelleted and
washed in PBS. Extraction and puriﬁcation of Tra2b
was carried out according the protocol previously
Nucleic Acids Research, 2011,Vol.39, No. 18 8093described (25), except that the Flag-Tra2b protein
was immunopuriﬁed on an anti-Flag-M2 afﬁnity gel
and eluted by competition with FLAG peptide
(SIGMA-ALDRICH). EMSAs were done as previously
described (25).
Antibodies
Proteins were detected by western blotting using
antibodies speciﬁc for GFP (Clontech 632381 Living
Colours A v monoclonal antibody), tubulin (Sigma
T5168 anti-a-tubulin monoclonal antibody), and Tra2b
(Abcam polyclonal antibody ab31353), and others used
previously (19,26).
RESULTS
Splicing activation of HIPK3-T is dependent on both the
RRM and RS domains of Tra2b
The HIPK3-T exon has a weak 50-splice site, although
there is a potentially stronger downstream 50-splice site
that is not selected by the spliceosome (position indicated
as an asterisk in Figure 1A). We used a pull down assay to
monitor association of nuclear proteins with the HIPK3-T
Figure 1. Modular organization of the HIPK3-T exon and activation by Tra2b through direct association with RNA. (A) z-score plot predicting the
splicing control sequences in and around the HIPK3-T exon. Regions of the exon above the threshold for exonic splicing enhancers are labelled
ESE1-4, and the region of the exon below the threshold for splicing silencers is labelled ESS. The architecture of the HIPK3-T exon and surrounding
intron, and sequence of the HIPK3-T exon and ﬂanking intron sequences are shown underneath. The strong 50-splice site downstream of HIPK3-T is
underlined, and its position in the sequence marked by an asterisk. (B) Schematic representation of Tra2b protein domains. (C) Analysis of the
splicing response of wild-type HIPK3-T to full length and domain deleted Tra2b-GFP fusion proteins, assayed by RT–PCR and capillary gel
electrophoresis, and presented as the percentage inclusion of HIPK3-T. All transfections and subsequent RNA analyses were performed at least in
triplicate. (D) Example of RT–PCR from cells transfected with HIPK3-T and different expression constructs encoding Tra2b proteins, and analysed
by capillary gel electrophoresis. +T=size of RT–PCR product including HIPK3-T exon. –T=size of RT–PCR product excluding HIPK3-T exon.
(E) Expression levels of each of the different wild-type and domain deleted Tra2b-GFP fusion proteins, assayed by western blotting from transfected
HEK293 cells in parallel with splicing assays. Levels of GFP fusion protein were measured using an a-GFP antibody, and levels of actin were
measured on the same ﬁlter using an a-actin antibody to provide a loading control for each lane.
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Name Mutation Systematic name Sequence
50-splice site mutations
A1 Weak native 50-splice site (0.16)
strengthened to 4.36
e+5,6 AA-GG GAGgttaaaaaa to GAGgttaggaaa
A2 Weak native 50-splice site (0.16)
strengthened to 7.15
e+5,6 AA-GT GAGgttaaaaaa to GAGgttagtaaa
A3 Deletion of the weak native
50- splice site
e.108A-C, e+2 T-C GAGgttaaaaaa to GCGgctaaaaaa
A4 Strong downstream 50-splice site
in weak native 50-splice site
position.
del e.107-109, del e+(1-34) deleted: GAGgttaaaaaaacatctttgcacttattctcaaata
ESE Mutations
B1 DESE1 e.5 G-A GATAaAAGATATTGAA
B2 DESE1 e.5 G-T GATAtAAGATATTGAA
B3 DESE2 e.86 A-T, 88 A-T GCTCAGAGGGAGGAtGtAT
B4 DESE2 e.84 G-T, 86 A-G, 88 A-T GGGAGtAgGtAATAGAAGA
B5 DESE3-4 B5x+y+z GGGAGGAAGAAATAGAtGATGCAaAA
GAGcATGGACT
B5x DESE3 e.95 a-t As shown in B5
B5y DESE4, peak a e.102 g-a As shown in B5
B5z DESE4, peak b e.108 g-c As shown in B5
B6 DESE 2-3-4 B3+B5 As shown in B3 and B5
Combinations of ESE and 50-splice site mutations
C1 DESE2 in the intermediate
strength (4.36) native 50-splice
site background
B3+A1 –
C2 DESE2 in the strong (7.31) native
50-splice site background
B3+A2 –
C3 DESE2 in the intermediate
strength (4.36) native 50-splice
site background
B4+A1 –
C4 DESE2 in the strong (7.31) native
50-splice site background
B4+A2 –
Mutations silencers downstream exon HIPK3-T
D1 Exonic silencer neutralized e.23 T-C, e.26 A-C TATTGAACATTTTcGTcTTTGGT
D2 Exonic silencer neutralized e.22 T-C, e.27 T-C TATTGAACATTTcTGTAcTTGGT
D3 Both silencer troughs in down-
stream intron neutralized
e+47 G-C +53 T-C CAGGTTAGGGGAcTCAAGcTTTAGTAA
D4 Second silencer trough in down-
stream intron neutralized
e+57 C insertion CAGGTTAGGGGAGTCAAGTTTcAGTAA
RNA sequences used for Pull Down and Gel Shifts (vector sequence in grey)
WT HIPK-3 exon aattgggtaccGATAGAAGATATTGAACATTTTTGTATTTGGTGGGGAGAGAGCTC
AGAGGGAGGAAGAAATAGAAGATGCAGAAGAGGATGGACTAATTGATGGA
GCAGAGTCTTTGAG
DS Downstream sequence aattgggtaccgttaaaaaaacatctttgcacttattctcaaatacaggttagg
B4 DESE2 aattgggtaccGATAGAAGATATTGAACATTTTTGTATTTGGTGGGGAGAGAGCTC
AGAGGGAGtAgGtAATAGAAGATGCAGAAGAGGATGGACTAATTGATGGA
GCAGAGTCTTTGAG
B5 DESE3-4 aattgggtaccGATAGAAGATATTGAACATTTTTGTATTTGGTGGGGAGAGAGCTC
AGAGGGAGGAAGAAATAGATGAtGCAaAAGAGcATGGACTAATTGATGGA
GCAGAGTCTTTGAG
B6 DESE2-3-4 aattgggtaccGATAGAAGATATTGAACATTTTTGTATTTGGTGGGGAGAGAGCTC
AGAGGGAGGAtGtAATAGATGATGCAaAAGAGcATGGACTAATTGATGGAG
CAGAGTCTTTGAG
The mutant name, systematic name, sequence effect of mutant are shown. Underneath the sequence of the HIPK3-T exon (uppercase) and
downstream intron (lower case, downstream 50-splice site is italicized). The ESEs are shown in coloured text consistent with Figure 1. Systematic
name: e. denotes the exonic position of the mutation, e+ denotes downstream intron.
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this strong 50-splice site. Consistent with the observed
physiological selection of the HIPK3-T exon, the exonic
region strongly bound some SR proteins and the SR-like
protein Tra2b (Figure 4C). In contrast, the downstream
region did not associate with SR proteins, but did bind
to hnRNPs, which are frequent splicing repressors
(Figure 4C).
Tra2b is the only known splicing activator of HIPK3-T
(19) and in preliminary experiments we found no other
interacting RNA binding proteins signiﬁcantly affected
its splicing inclusion. To test if direct RNA binding was
required for Tra2b-mediated splicing activation of
HIPK3-T, we ﬁrst inactivated the RRM with an independ-
ent deletion of RNP1 and deletion of the entire RRM
(Figure 1B). We then tested the activity of the resulting
mutants on splicing of the wild-type HIPK3-T exon by
co-transfection experiments in HEK293 cells. In contrast
to the wild-type Tra2b-GFP protein, mutants affecting
the RRM (DRNP1 and DRRM) were unable to
stimulate HIPK3-T exon inclusion (Figure 1C, D lanes 4
and 5 compared to lane 2) indicating direct binding of
Tra2b-GFP to HIPK3-T target RNA is required for
splicing activation. In several other SR protein splicing
regulators, multiple domains can play partially redundant
functions (27–30). We also deleted the N-terminal RS-rich
region to test if the N- and C-terminal RS domains of
Tra2b are functionally redundant, and found that Tra2b
proteins lacking the N-terminal RS domain were unable to
support splicing activation of HIPK3-T (Figure 1C and D
lane 3). We observed equal levels of GFP-fusion proteins
by western blotting (Figure 1E) for each of the full length
and deletion derivatives of Tra2b, and these localized in
the nucleus [data not shown, and (31)].
The amplitude of Tra2b-mediated splicing
activation of HIPK3-T is dependent on intrinsic
exon strength
HIPK3-T has a somewhat weak 50-splice site (GAG|
gttaaa), which has a score of 0.16 measured using a
maximum entropy model (http://genes.mit.edu/burgelab,
where a score of  11 represents a perfect splice site). We
tested whether this weak 50-splice site normally contributes
to exon skipping by mutating HIPK3-T to contain an
intermediate strength (GAG|gttagg, score: 4.36 for con-
struct A1) or strong 50-splice site (GAG|gttagt, score:
7.15 for construct A2). Full details of all HIPK3-T
mutants used in this study are given in Table 1. Both
improved splice sites resulted in the HIPK3-T exon
being more efﬁciently spliced even without the addition
of exogenous Tra2b (compare Columns 1 with 3 and 5,
Figure 2B). Therefore, the level of HIPK3-T exon inclu-
sion shows a direct correlation to splice site strength,
indicating that the weakness of the 50-splice site is a
major negative element restricting HIPK3-T exon splicing.
We next analysed the magnitude of the splicing response
of the above 50-splice site variants of HIPK3-T to Tra2b
expression (Figure 2B, Columns 2, 4 and 6). To compare
differences between splicing responses of different
pre-mRNAs over the full dynamic range we monitored
HIPK3-T splicing activation both as a percentage of
HIPK3-T inclusion (showing overall levels of splicing in-
clusion, Figure 2B), and using a natural logarithm-score
plot (Log-score, Figure 2C, see ‘Materials and Methods’
section). As expected, splicing of each of the HIPK3-T
exons was activated by Tra2b, but with improved overall
percentage splicing inclusion for the exons with strong
(A2) or intermediate (A1) 50-splice sites (Figure 3C).
Importantly, plotting the difference in log-scores before
and after co-transfection of Tra2b indicated a clear
trend in splicing activation between pre-mRNAs: the
splicing response of each of the pre-mRNAs to Tra2b
was inversely correlated to 50-splice site strength
(Figure 2D). Hence weaker HIPK3-T exons respond
more speciﬁcally to Tra2b-mediated splicing activation.
Figure 2. (A) The splicing response of HIPK3-T to Tra2b correlates
with intrinsic exon strength deﬁned by 50-splice site. Correlation
between 50-splice site strength and splicing response of HIPK3-T in
terms of percentage splicing inclusion in response to Tra2b (B), log-
score plot for response to Tra2b (C), or difference in log scores (D). A1
and A2 variants have intermediate strength or strong natural 50-splice site.
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To identify the splicing control elements that might
mediate Tra2b-mediated HIPK3-T splicing activation we
next analysed the entire exon sequence and ﬂanking intron
sequences for octamers predictive of splicing enhancers
and silencers based on the bioinformatic approaches of
Zhang and Chasin (32–34). Detailed analysis of the result-
ing octamer z-score plots indicated four distinct peaks in
the HIPK3-T exon above the threshold value correspond-
ing with putative Exonic Splicing Enhancers (ESEs),
and a single Exonic Splicing Silencing Region (ESS)
(Figure 1A). We name individual predicted ESEs here
ESE 1–4 (Figure 1A). Each of the ESEs was GAA/
AGA-rich (designated hereafter AGAA-rich), consistent
with the known binding site for Tra2b (15,16,35)
Splicing activation of HIPK3-T by Tra2b requires
the full complement of four ESEs
We next sought to precisely map sequences in the
HIPK3-T exon that were responsive to Tra2b. Using the
results of the HIPK3-T exon sequence analysis shown in
Figure 1A, we systematically mutagenized each putative
Tra2b responsive ESE with multiple single mutations
(Figure 3 and Table 1). In each case site directed muta-
genesis was designed using an in-house software based on
the octamer z-scores, along with other matrices including
HSF and ESE ﬁnder (36–38) to ensure that no predicted
splicing silencer or enhancer elements were introduced
into the HIPK3-T sequence (see ‘Materials and
Methods’ section).
To our surprise, single mutation of any one of the four
ESE regions was sufﬁcient to completely prevent
HIPK3-T splicing activation (Figure 3B). No HIPK3-T
splicing inclusion was observed for pre-mRNAs made
from constructs B1, B2 (disruption of ESE1), B3, B4 (dis-
ruption of ESE2), or B5 (disruption of ESE 3 and 4)
(Figure 3B, Columns 1–8, Table 1 and data not shown).
Further dissection of B5 into the individual point muta-
tions B5x (disruption of ESE3), B5y (disruption of the ﬁrst
sub-peak of ESE4) and B5z (disruption of the second
sub-peak of ESE4) indicated that only single point muta-
tions in ESE3 (B5x) or in the ﬁrst enhancer sub-peak of
ESE4 (B5y) completely disabled Tra2b-mediated splicing
activation (compare Columns 1 and 2 with Columns 9–12,
Figure 3B). Disruption of the second sub-peak alone
in ESE4 (B5z) only resulted in a partial loss of
Tra2b-mediated splicing activation, most probably
because the mutation preserves a AGAAG sequence in
the ﬁrst half of ESE4 (Columns 13, 14, Figure 3B).
HIPK3-T exons lacking single ESEs are still able to
bind Tra2b protein
The above results indicate that ESEs 1–4 as deﬁned by our
approach are indeed true individual ESEs, and also each
Figure 3. Each of four Exonic Splicing Enhancer Regions (ESEs) are essential for Tra2b-mediated splicing activation. (A) The z-score plots of the
wild-type HIPK3-T exon (black), superimposed with z-score plots for each of the point mutants which affected individual ESEs (shown as coloured
lines, with the changed nucleotide indicated as a broken line). See also Table 1 for a complete description of all mutants used in this study. (B) The
percentage exon inclusion obtained after transfection of each of these point mutants after transfection with GFP or Tra2b (+lane).
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vation of HIPK3-T. Each of the identiﬁed ESEs within
HIPK3-T contains at least one AGAA motif, consistent
with the known speciﬁc binding site of Tra2b protein
(15,16). However, after each single ESE disruption there
were three AGAA-containing ESEs remaining, so we pre-
dicted that such mutated HIPK3-T exons should still be
able to bind to Tra2b protein even though splicing activa-
tion was lost.
To test this prediction we carried out gel shift experi-
ments. In preliminary experiments we identiﬁed strong
binding of bacterially expressed protein containing the
RRM of Tra2b to the HIPK3-T exon and no binding
to the downstream intronic RNA (data not shown).
This indicated that the RRM was important for
interaction with HIPK3-T in vitro. Since Tra2b protein
can multimerize via its RS domains (31), full length
Tra2b protein was then expressed and puriﬁed from mam-
malian cells (Figure 4B). Puriﬁed protein was then used to
test in vitro association with radiolabelled RNAs
comprising either wild-type HIPK3-T, HIPK3-T exon
with a single ESE disruption (B4), HIPK3-T exon with a
double ESE disruption (B5), and HIPK3-T exon with a
triple ESE disruption (B6).
Strong and almost complete Tra2b binding was
observed to wild-type HIPK3-T exon even at the lowest
concentration of added Tra2b (Figure 4A, lanes 1–5 and
16–20). Additional band shifts were obtained with
increasing concentrations of Tra2b, most likely due to
binding of several Tra2b molecules to the T exon
Figure 4. ESE-depleted versions of HIPK3-T are still able to bind Tra2b.( A) Gel shift experiments (Electrophoretic Mobility Shift Assays) were
carried out with either wild-type HIPK3-T RNA, or HIPK3-T variants with different ESE proﬁles. Radiolabelled RNAs were shifted with 0, 50 and
100ng added Tra2b protein. The sequences of these RNAs are given in Table 1. (B) Puriﬁed full length Tra2b Flag tagged protein. (C) RNA binding
proteins associated with the HIPK3-T exon and downstream intronic region are associated with a number of RNA splicing regulators.
wt=wild-type HIPK3-T exon, DS=downstream RNA.
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observed for both wild-type and mutant B4 HIPK3-T
exons. Very slightly less strong shifts at low Tra2b con-
centrations were observed after single ESE disruption
(lanes 6–10), indicating that HIPK3-T exons lacking
single ESEs are still able to bind Tra2b efﬁciently.
Consistent with expectations from the AGAA-rich ESE
elements, less RNA was shifted for probes containing
double (B5, Figure 4A, lanes 21–25) and particularly
triple ESE mutations (B6, Figure 4A, lanes 11–15).
Indeed, at the lower concentrations of Tra2b protein
tested (10 and 20ng) a signiﬁcant part of the B5 and B6
RNA remained un-shifted, and the highest molecular
weight band shift was not observed in the B6 mutant
even with the highest concentration of Tra2b (lane 15
compared to 5).
We also compared the binding of wild-type HIPK3-T to
mutant RNAs with double ESE disruptions (Figure 4C,
wt and B5) by pull down from nuclear extracts. No dif-
ference in binding of Tra2b relative to ASF/SF2 was
observed for any of these RNAs. Taken together these
data indicate that each of the identiﬁed putative ESEs
are able to interact with Tra2b protein, and mutation of
one (B4) or two (B5) ESEs does not dramatically change
the interaction properties of the exon. However, while B5
and wild-type RNAs form similar sized protein–RNA
complexes, in vivo only the wild-type RNA sequence
supports splicing activation by Tra2b.
Splicing of HIPK3-T exon variants with stronger
splice sites need fewer ESEs for splicing activation,
but activate with lower amplitude
Taken together the above experiments indicated that while
in vivo splicing activation of the HIPK3-T exon is severely
compromised after loss of only a single ESE sequence,
Tra2b protein is still able to bind to HIPK3-T RNA
in vitro efﬁciently after single ESE disruption. Hence
although Tra2b binding might take place to a reduced
complement of ESEs, four functional ESEs are the
minimum required to enable splicing activation of the
wild-type HIPK3-T exon by Tra2b.
We further tested whether a combination of three ESEs,
although non-functional in the wild-type context of exon
HIPK3-T, might retain some splicing enhancer activity by
analysing splicing of engineered versions of HIPK3-T with
stronger splice sites. ESE2 was mutated in the context of
both the intermediate (to give C1) and strong 50-splice site
(to give C2) derivatives of HIPK3-T. We then tested each
of these engineered HIPK3-T exon variants for splicing
activation by Tra2b (Figure 5). Consistent with Tra2b
still binding to ESE-disrupted HIPK3-T exons, ESE2
removal reduced rather than prevented Tra2b-mediated
splicing in the context of an improved 50-splice site
(Figure 5B and C, Columns 3–6). As previously
observed, pre-mRNAs made from B3 were not activated
for splicing by Tra2b (Figure 5B, Columns 1–2).
Analysis of this data by plotting the difference in the
log-score of splicing activation before and after
co-transfection with Tra2b in Figure 5D again showed a
clear correlation between the quantitative response to
Tra2b and the overall intrinsic strength of the exon.
The pre-mRNA with the intermediate 50-splice site (C1)
showed a strongly increased responsiveness to Tra2b after
ESE2 mutation (compare the log score plot for C1 in
Figure 5 to wt and A1 in Figure 2), although splicing in-
clusion levels were reduced comparatively to the wild-type
HIPK3-T substrate. This was exactly the trend described
in the previous section for the wild-type combination of
four ESEs. HIPK3-T variants with the strong 50-splice site
that either contained an ESE2 mutation (C2), or not (A2)
showed very similar behaviour showing these pre-mRNAs
are less dependent on Tra2b for splicing inclusion
(compare A2 and C2 in Figures 2 and 5 middle and
bottom panels). Identical results were also obtained on
combining another single ESE disruption mutant (B4)
with the intermediate and strong 50-splice site mutants
(mutations C3 and C4, Table 1, and data not shown).
Figure 5. HIPK3-T exon variants with stronger splice sites have a
reduced ESE content requirement for splicing activation, but are
activated with a lower amplitude. (A) Organisation of pre-mRNAs
used in this experiment. Splicing responses of HIPK3-T exon variants
B3, C1 and C2, described fully in Table 1, are shown in terms of
percentage splicing inclusion in response to Tra2b (B), Log-score plot
for response to Tra2b (C), or difference in log scores (D).
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with an additive mode of splicing activation
The results shown in Figures 2 and 5 indicate that only the
combination of the four ESEs and the weak 50-splice site
present in the wild-type HIPK3-T exon are able to induce
a speciﬁc and efﬁcient on/off splicing switch in response
to Tra2b expression. These results are consistent with
two conceptually different models of HIPK3-T splicing
regulation (Figure 6A). The ﬁrst ‘splicing threshold’
model predicts that concomitant occupancy of each of a
minimum number of four ESE sites would be essential for
HIPK3-T splicing activation. According this model,
decreasing the ESE number would totally incapacitate
the exon with regards to splicing activation and increasing
Tra2b concentration within the cell should not be able to
rescue splicing.
The second ‘kinetic probability’ model is based on the
probability of Tra2b occupancy of the HIPK3-T exon,
through analogy with the model for Tra2 protein regula-
tion of Drosophila Dsx splicing (17). In this model,
multiple ESE sites would increase the probability of
co-residency of Tra2b and U1 snRNP on the HIPK3-T
exon, and ensure splicing activation on nascent RNA
before the transcription of downstream competing exons
Figure 6. Splicing of ESE depleted versions of HIPK3-T is not rescued by higher concentrations of nuclear Tra2b protein. (A) Two possible models
of HIPK3-T splicing inclusion in response to Tra2b.( B) Graphs of dose responses of wild-type HIPK3-T and mutant HIPK3-T B1 and B3 to
increasing concentrations of Tra2b (transfections of 300, 900 and 1500ng of Tra2b expressing plasmid). (C) Levels of GFP-containing proteins were
detected by a-GFP (left panel); Tra2b protein detected using a-Tra2b (middle panel); and a-tubulin (right panel) measured in parallel in transfected
cells.
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only one ESE may be sufﬁcient for activation. Thus
increasing the nuclear concentration of Tra2b might com-
pensate for the decreased ESE content by increasing the
probability of ESE occupancy.
In order to test between the predictions of these two
models, we carried out transfections with a gradient of
different Tra2b concentrations. Splicing of the wild-type
HIPK3-T exon was efﬁciently activated in response to
increasing Tra2b-GFP. Although B1 or B3, with three of
four ESEs remaining, showed a minimal response to
Tra2b, only very low levels of exon inclusion are
achieved (Figure 6), and thus even high levels of Tra2b
cannot compensate for an incomplete set of ESEs even in
very high concentrations of Tra2b. Western analysis of
transfected cells is shown in Figure 6C, which shows the
increase in Tra2b-GFP along the concentration gradient,
and also the levels of endogenous Tra2b protein and
alpha-tubulin in the same cells.
Splicing repression of a strong downstream 50-splice site
enables the HIPK3-T splicing switch to operate
The above data indicate that a combination of four ESEs
coupled to a weak 50-splice site enable an efﬁcient on/off
splicing switch in response to increasing concentrations of
Tra2b. However, proper operation of the HIPK3-T
splicing switch system would require either any nearby
competing stronger 50-splice sites not dependent on
Tra2b activation to be actively repressed, or for the
Tra2b protein to activate splicing at the upstream
50-splice site.
Sequence analysis indicated that immediately down-
stream of HIPK3-T is a strong 50-splice site consensus
sequence that is in fact not selected by the spliceosome
in vivo (19). This sequence has a score of 6.25 compared
to the natural 50-splice site which only measures 0.16 using
a maximum entropy model (http://genes.mit.edu/
burgelab). To test whether this downstream splice site is
actively repressed, or whether Tra2b preferentially acti-
vates the upstream 50-splice site irrespective of intrinsic
splice site strength, we ﬁrst removed the weak upstream
natural 50-splice site (mutant A3). In this case we only
observed very weak splicing at the downstream site
(Figure 7, Columns 3 and 4). This indicates that the
upstream natural 50-splice site is indeed preferentially
activated by the Tra2b sites in the exon, but the down-
stream splice site is functional at some level since it is
activated by Tra2b when the upstream weaker site is
absent.
To test for active repression of the downstream site we
then replaced the natural 50-splice site with the down-
stream stronger 50-splice site, by simply deleting 37nt off
the end of the exon in place of the weak natural 50-splice
site (mutant A4). In this case we observed no splicing in-
clusion even with transfected Tra2b (Figure 7, Columns 5
and 6). This conﬁrms that this downstream 50-splice site
region is also actively repressed, and moving the repressive
elements closer to the HIPK3-T exon may repress splicing
inclusion. Consistent with this model, the downstream
intronic region binds a high concentration of hnRNPs,
but not SR proteins (Figure 4C).
DISCUSSION
Alternative splice site selection is regulated by ubiquitous-
ly expressed splicing factors that act on sequences located
within or in the vicinity of exons. This gives rise to at least
two variables for each exon, namely, the complement of
splicing factors available in the target tissue, which is often
controlled within very narrow concentration ranges; and
secondly, the intrinsic strength of the exon reﬂected by its
splice site strengths and complement of positive and
negative regulatory elements. The recognition of an exon
is based on a ﬁnely regulated balance between these two
variables.
It has been a conceptual challenge in the ﬁeld to explain
how individual exons are regulated in a tissue or cell
speciﬁc manner in response to ubiquitously expressed
factors. We present here evidence for an interesting and
novel splicing switch mechanism, that relies on a balance
between the number of binding sites for a single splicing
factor coupled to 50-splice site strength. In the HIPK3-T
system, a very weak exon which is not recognized in any
tissue type tested other than testis contains an array of
AGAA-rich ESEs and is activated by Tra2b. Although
the HIPK3-T exon binds in nuclear extracts to a number
of splicing regulator proteins in addition to Tra2b (19),
Figure 7. The stronger 50-splice site downstream of the HIPK3-T exon
is repressed. (A) Organization of the different pre-mRNAs used in this
experiment. (B) Percentage of splicing inclusion of each of the engin-
eered HIPK3-T exons at the downstream splice site in response
to co-transfection of either GFP or Tra2b-GFP. (C) Splicing
inclusion of each of the HIPK3-T exon derivativesmonitored by a
log-score plot.
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ASF/SF2 which may also bind to a GAA-rich target
sequence (23,39), could activate or repress this exon in
in vivo minigene experiments (data not shown). In
contrast to transfected cells, in vitro splicing substrates
containing the HIPK3-T splicing enhancer do require
addition of ASF/SF2 to enable splicing activation of a
50-splice site by Tra2b (19). This in vitro requirement is
consistent with the need for exogenous SR proteins to
support splicing of other pre-mRNA substrates in S100
extracts, since Tra2b cannot provide this additional
activity.
Interestingly, loss of even a single ESE sequence
resulted in complete loss of exon activation which could
not be rescued by elevating levels of Tra2b. An array of
ESEs responsive to a single splicing factor where disrup-
tion of just a single ESE results in loss of exon recognition
is novel and consistent with a model in which exon
strength is ﬁnely balanced with ESE content to enable
an efﬁcient splicing switch to take place in the testis in
response to speciﬁcally to Tra2b concentration. Such
gauges may be used by exons to measure the nuclear con-
centration of speciﬁc splicing regulators that are ubiqui-
tously expressed but at varying tissue-speciﬁc levels, and
thus establish cell type-speciﬁc splicing responses.
Importantly, to enable these gauges to work properly
potentially stronger consensus downstream 50-splice sites
would need to be actively repressed, or else these stronger
sites would be constitutively selected by the spliceosome.
We have experimentally conﬁrmed repression of a poten-
tially competing 50-splice site for HIPK3-T. Similar repres-
sion of downstream 50-splice sites has also been observed
for other regulated exons with weak 50-splice sites (40).
While HIPK3-T contains multiple similar ESEs all re-
sponding to Tra2b concentrations, splicing of other
exons have been reported to be individually dependent
on multiple different functional ESEs responsive to differ-
ent RNA binding proteins (34). This suggests that a model
of splicing control in which multiple ESEs respond to the
nuclear concentration of speciﬁc RNA binding proteins
might extend also to combinatorial control. The number
of Tra2b binding sites required within an exon to establish
a splicing response is likely to depend on splice site
strength and other splicing signals. For example, the in-
clusion of another Tra2b-responsive exon such as SMN2
exon 7, which has a single Tra2b binding site, additionally
depends on binding of hnRNPG and SRp30c (15).
Our analysis here of the human testis speciﬁc HIPK3-T
exon makes interesting comparison to the mammalian
SFRS10 exon 2 which is also regulated by Tra2b.
The SFRS10 gene encodes Tra2b protein, and exon 2 is
a ubiquitously spliced poison exon which enables auto-
regulation in response to increasing levels of Tra2b
protein (41). Similarly to HIPK3-T, SFRS10 exon 2 has
4 AGAA rich ESEs distributed all along the exon.
However, SFRS10 exon 2 has a moderate 50-splice site
rather than the weak 50-splice site found in HIPK3-T.
In contrast to the HIPK3-T exon, inactivation of one
ESE in the SFRS10 exon 2 does not completely abolish
Tra2b activation, likely due to the associated moderately
strong 50-splice site. Hence the HIPK3-T and SFRS10
exons represent two prototypical examples of alternative
exons regulated by the generally expressed splicing regu-
lator protein Tra2b. Splicing inclusion can be either highly
tissue-speciﬁc as for HIPK3-T or differentially regulated
in various tissues as in SFRS10 exon 2. A general principle
suggested from these two examples is that the anatomic
spectrum of different Tra2b-responsive exons may be es-
tablished in response to Tra2b concentration through an
inter-play between the number of Tra2b-responsive ESEs
and associated splice site strengths and other local splicing
signals. Tra2b-responsive exons with stronger 50-splice
sites might be activated more ubiquitously than weaker
exons like HIPK3-T with weaker 50-splice sites. With
these weaker exons, splicing inclusion would be switched
on in speciﬁc tissues like the testis with elevated Tra2b
concentrations and/or down-regulation of some splicing
repressors (42). It is also possible that HIPK3-T is under
regulation by trans-acting factors like PP1 which regulate
Tra2b activity (43).
We propose an array of Tra2b binding sites within the
HIPK3-T exon are deciphered to give tissue speciﬁc
patterns of splicing activation in response to the expres-
sion levels of Tra2b. Very similar mechanisms of Tra2
splicing regulation have been shown to take place in
Drosophila, both on the 30-splice site (44) and on
50-splice site regions (45). Activation of the Doublesex
female-speciﬁc 30-splice site is modulated in response to
the number of multi-site enhancers for Tra2, and activa-
tion increases linearly rather than synergistically in
response to this ESE number (17). In ﬂies, increases in
numbers of Tra2-responsive ESEs have been suggested
to increase the probability of assembly of a splicing acti-
vator complex on Doublesex pre-mRNA, rather than
enabling cooperative assembly of multiple binding
splicing complexes containing Tra2. In this case the
number of enhancer binding sites may inﬂuence the prob-
ability of U1 snRNP binding to the alternatively spliced
exon. However, despite potential subtle mechanistic dif-
ferences, human and ﬂy orthologues of Tra2 protein seem
to regulate splicing switches in a somewhat analogous
fashion, both requiring assembly of Tra2 proteins on a
responsive gauge. Regulated splice variants of other
Drosophila mRNAs are similarly made in response to dif-
ferent threshold values of Tra2 concentrations in different
tissues (18).
In this study we also found that Tra2b has a magniﬁed
activating effect on intrinsically weak exons. This
magniﬁed effect makes the HIPK3-T splicing switch
more efﬁcient. Since the testis has an increased Tra2b con-
centration (19), this observed splicing activation effect of
Tra2b on weakly deﬁned exons is also likely to apply to
other intrinsically weak exons with Tra2b binding sites,
and thus might contribute to the high overall levels of
exon inclusion observed in the testis (8–11).
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